Skip to content
Bored Studies
RecruitingPhase 2

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

AstraZeneca · NCT07276581

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
320
US sites recruiting
22
Study start
December 15, 2025
Record last updated
October 9, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.

Being studied: AZD1163; Placebo

Conditions: Rheumatoid Arthritis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria
  • Inclusion
  • Diagnosed with adult-onset RA as defined by the 2010 ACR/EULAR classification criteria for at least 12 weeks prior to screening.
  • Moderately-to-severely active RA as defined by: a. >= 6 swollen joints on 66SJC and >= 6 tender joints on 68TJC; b. CRP > upper limit of normal.
  • Have a positive ACPA at screening.
  • A history of inadequate response, or loss of response, or intolerance to: a. at least one csDMARD treatment, AND/OR b. At least one and at most 2 TNFi.
  • A history of at least 12 weeks treatment and >= 4 weeks stable on a csDMARD and/or SC TNFi prior to the day of randomisation.
  • Exclusion
  • History or evidence of an alternate autoimmune or other condition that could confound the diagnosis of RA. Participants with RA and secondary Sjogren's disease are eligible.
  • Have received or planning to receive any biologic DMARDs (except for TNFi) or targeted synthetic DMARDs.

Recruiting US locations

Study contacts (from the official record)

  • AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
All arthritis studies in Arizona →
A Study to Investigate Efficacy and Safety of AZD1163 in… (NCT07276581) | Bored Studies